146 related articles for article (PubMed ID: 2804976)
1. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.
Isaacs JT
Cancer Res; 1989 Nov; 49(22):6290-4. PubMed ID: 2804976
[TBL] [Abstract][Full Text] [Related]
2. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
English HF; Heitjan DF; Lancaster S; Santen RJ
Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359
[TBL] [Abstract][Full Text] [Related]
4. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.
Isaacs JT; Coffey DS
Cancer Res; 1981 Dec; 41(12 Pt 1):5070-5. PubMed ID: 7307008
[TBL] [Abstract][Full Text] [Related]
5. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas.
Isaacs JT
Cancer Res; 1982 Dec; 42(12):5010-4. PubMed ID: 6215981
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas.
Ellis WJ; Isaacs JT
Cancer Res; 1985 Dec; 45(12 Pt 1):6041-50. PubMed ID: 4063963
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of E-cadherin in the progression of rat prostatic cancer.
Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA
Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
9. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
[TBL] [Abstract][Full Text] [Related]
10. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
[TBL] [Abstract][Full Text] [Related]
11. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
12. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
13. Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J
Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
[TBL] [Abstract][Full Text] [Related]
14. Programmed cell death as a new target for prostatic cancer therapy.
Kyprianou N; Martikainen P; Davis L; English HF; Isaacs JT
Cancer Surv; 1991; 11():265-77. PubMed ID: 1841755
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
16. Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss.
Humphries JE; Isaacs JT
Cancer Res; 1982 Aug; 42(8):3148-56. PubMed ID: 7093958
[TBL] [Abstract][Full Text] [Related]
17. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
18. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide.
Vukanovic J; Isaacs JT
Cancer Res; 1995 Aug; 55(16):3517-20. PubMed ID: 7543015
[TBL] [Abstract][Full Text] [Related]
19. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
Smolev JK; Heston WD; Scott WW; Coffey DS
Cancer Treat Rep; 1977; 61(2):273-87. PubMed ID: 872132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
